PHARMALINK

Idorsia Expands QUVIVIQ Access to Gulf States Through Pharmalink Partnership

- Idorsia has entered an exclusive distribution agreement with Pharmalink for QUVIVIQ (daridorexant) across five Gulf Cooperation Council countries including UAE, Kuwait, Qatar, Oman, and Bahrain. - QUVIVIQ represents a novel dual orexin receptor antagonist that targets overactive wake signaling without broadly suppressing brain activity, offering an alternative to traditional hypnotics. - Clinical trials published in The Lancet Neurology demonstrated significant improvements in sleep onset, maintenance, and daytime functioning at both 25mg and 50mg doses compared to placebo. - The partnership leverages Pharmalink's established infrastructure of over 1,800 employees and 200+ pharmacies to address the high prevalence of insomnia in the GCC region.